Abemaciclib

BRAND NAMES

Verzenios: Abemaciclib is a targeted therapy medication used to treat certain types of breast cancer, primarily known by the brand name Verzenio (in the US) and Verzenios (in Europe).

MECHANISM OF ACTION

Abemaciclib selectively inhibits cyclin-dependent kinases 4 and 6 (CDK4/6), which are essential for cell cycle progression from the G1 phase to the S phase. Normally, these kinases phosphorylate the retinoblastoma (Rb) protein, inactivating it and allowing DNA replication. Abemaciclib prevents this phosphorylation, keeping Rb in its active form and causing arrest of the cell cycle in the G1 phase. This inhibition reduces cancer cell proliferation and may also promote apoptosis and cellular senescence.

PHARMACOKINETICS

Absorption

Abemaciclib is well absorbed following oral administration, reaching peak plasma concentrations within 4–8 hours. It exhibits good oral bioavailability and maintains consistent plasma levels with regular dosing.

Distribution

The drug is widely distributed throughout body tissues, with a high volume of distribution. It is highly bound to plasma proteins (greater than 95%) and is capable of crossing the blood–brain barrier, allowing it to act in the central nervous system.

Metabolism

Abemaciclib is largely broken down in the liver, mainly through the action of the CYP3A4 enzyme. It undergoes oxidative metabolism to produce several metabolites, some of which are pharmacologically active and contribute to its therapeutic effects.

Excretion

The drug is mainly eliminated through the feces via the biliary route, while a smaller portion is excreted in urine. It has an elimination half-life of approximately 18–25 hours.

PHARMACODYNAMICS

Abemaciclib exerts its pharmacological effect by inhibiting CDK4/6 activity, thereby preventing phosphorylation of the retinoblastoma protein. This results in cell cycle arrest at the G1 phase, reducing tumor cell proliferation. Additionally, it may induce apoptosis and cellular senescence, enhancing its anticancer activity.

ADMINISTRATION

Abemaciclib is administered orally in tablet form and is usually taken twice daily at approximately the same time each day. It may be taken with or without food and is used either as monotherapy or in combination with endocrine therapy depending on the clinical condition.

DOSAGE AND STRENGTH

Abemaciclib is available in tablet strengths of 50 mg, 100 mg, 150 mg, and 200 mg. The typical adult dose is 150 mg, taken twice a day. Dose reductions to 100 mg or 50 mg twice daily may be required based on patient tolerance and the occurrence of adverse effects.

DRUG INTERACTIONS

Abemaciclib has significant interactions with drugs affecting the CYP3A4 enzyme system. Strong CYP3A4 inhibitors such as ketoconazole, clarithromycin, and ritonavir can increase drug levels and toxicity risk, while strong inducers like rifampin, carbamazepine, phenytoin, and St. John’s wort can reduce its effectiveness. It may also increase plasma concentrations of drugs such as digoxin, requiring careful monitoring.

FOOD INTERACTIONS

Abemaciclib can be taken with or without food; however, consumption of grapefruit or grapefruit juice should be avoided as it can inhibit CYP3A4 and increase drug levels, leading to enhanced toxicity. Alcohol should be used cautiously as it may worsen gastrointestinal irritation and liver-related side effects.

CONTRAINDICATIONS

Abemaciclib should not be used in patients who have a known allergy to the drug or any of its ingredients. It should be used with caution or avoided in patients with severe hepatic impairment, as liver metabolism plays a major role in its clearance.

SIDE EFFECTS

Common Side Effects

• Diarrhea (most frequent) 

• Fatigue / weakness 

• Nausea and vomiting 

• Loss of appetite 

• Abdominal pain 

• Infections 

Hematological Effects

• Neutropenia (low neutrophil count) 

• Anemia 

• Thrombocytopenia 

Liver-related Effects

• Elevated liver enzymes (AST, ALT) 

• Hepatotoxicity (in some cases) 

Gastrointestinal Effects

• Diarrhea (may be severe) 

• Dehydration (secondary to diarrhea)

OVERDOSE

In cases of overdose, there is no specific antidote for abemaciclib. Management is mainly supportive and symptomatic, including monitoring of vital signs, blood counts, and liver function. Severe toxicity may require hospitalization and dose interruption or discontinuation.

TOXICITY

Abemaciclib toxicity primarily includes gastrointestinal effects such as severe diarrhea, hematologic toxicity like neutropenia, and hepatotoxicity indicated by elevated liver enzymes. Rare but serious toxicities include venous thromboembolism and interstitial lung disease. Regular monitoring and dose adjustments are essential to minimize toxic effects.